<DOC>
	<DOCNO>NCT00585104</DOCNO>
	<brief_summary>This study test hypothesis mechanical efficiency measure pressure-volume loop assessment improve short-term treatment intravenous levosimendan . Levosimendan ( SimdaxTM , Abbott Laboratories , Abbott Park , IL ) calcium sensitizer show beneficial hemodynamic effect patient decompensated congestive heart failure ( CHF ) . Levosimendan new calcium sensitizer bind troponin C. This agent approve Europe treatment heart failure patient . In United States , agent currently phase III investigation intravenous treatment patient acutely decompensated HF dyspnea rest minimal activity . Levosimendan study patient acute HF consider experimental United States population .</brief_summary>
	<brief_title>Myocardial Hemodynamic Effects Levosimendan</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>All patient either sinus pace atrial rhythm atrioventricular synchrony electrocardiography All patient history heart failure diagnose clinically history prior symptom sign heart failure least one follow symptom within past month : dyspnea exertion , orthopnea , paroxysmal nocturnal dyspnea , pedal edema In asymptomatic patient , patient may enrol least one follow clinical sign heart failure : left ventricular third and/or fourth heart sound , jugular venous pressure &gt; 7 mmHg , sustain leave ventricular impulse , pulmonary congestion auscultation patient echocardiographic evidence leave ventricular dysfunction Under age 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>